A new study shows that targeting a particular nuclear protein may provide an effective approach for treating triple-negative breast cancer.
A protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells, according to new research.
Investigators with The Cancer Genome Atlas (TCGA) Research Network have identified new potential therapeutic targets for a major form of bladder cancer.
Androgen and vitamin D receptors can be targeted in breast cancer, according to new research.
The most common genetic subtype of lung cancer, which has long defied treatment with targeted therapies, has had its growth halted by a combination of two drugs already in use in laboratory and animal studies.
Vemurafenib, a BRAF inhibitor that has been approved as a treatment for advanced melanomas, has also proved successful in treating hairy cell leukemia.
Targeted treatments for acute promyelocytic leukemia cause a cascade of molecular events that lead to cellular senescence and recovery. This action model could be activated in other types of cancers.
Research has not only shown that HER2-positive breast cancer can be classified into four different subtypes, but has also unmasked a subtype showing both a greater response to and increased benefit from chemotherapy and anti-HER2 therapy.
A gene mutation associated with several types of cancer also may be responsible for a rare but debilitating brain tumor called papillary craniopharyngioma.
The most comprehensive genetic study to date of the blood cancer multiple myeloma has revealed that the genetic landscape of the disease may be more complicated than previously thought.
A new technique targets metastasizing cancer cells that are traveling through the bloodstream by hitching cancer-killing proteins on white blood cells.
Therapies specifically targeting the molecular profile of non-small cell lung cancer (NSCLC) with mutated KRAS, a cancer-causing protein, are the most effective treatment strategies for patients with NSCLC.
A new study helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia.
ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers, which implies that drugs that target ALK and ROS1 in lung cancer may also have applications for colorectal cancer.
A deadly, rare type of soft-tissue cancer may be completely eradicated simply by inhibiting a key protein involved in its growth, according to a new research report.
Combining the monoclonal antibody gemtuzumab with standard chemotherapy significantly reduced the risk of relapse and increased rates of disease-free survival in pediatric patients with AML. Posttreatment relapse rates are a major indicator of potential for long-term survival in children with the disease.
A toxin linked to a targeted monoclonal antibody has shown compelling antitumor activity in patients with non-Hodgkin lymphomas (NHLs) who were no longer responding to treatment, according to a new report.
A promising new approach to treating colorectal cancer involves disarming the gene that drives self-renewal in the stem cells that are the root cause of disease, treatment resistance, and relapse. Colorectal cancer is the third leading cause of cancer-related death in the Western world.
In separate studies on CEBPA mutations in AML subtypes, researchers successfully identified a gene known as Sox4 as a potential therapeutic target along with a class of anticancer drugs—histone deacetylase (HDAC) inhibitors—as potential candidates in the treatment of AML subtypes.
Selectively targeting only cancer cells could help to avoid healthy cells and side effects from treatments.
A new study is using genomic sequencing to develop customized treatments for men with castration-resistant prostate cancer.
A phase II study is the first to show that adding two targeted therapy drugs to the standard chemotherapy regimen is safe and effective as first-line treatment of advanced non-small cell lung cancer.
A small-molecule inhibitor of CDK 4/6 being developed showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies.
A highly targeted cancer radiation therapy may offer a safe and effective treatment option for elderly patients with pancreatic cancer who are unable to undergo surgery or combined chemotherapy and radiation therapy.
Substantial tumor regressions among some patients with advanced pancreatic cancer occurred in a recent clinical trial that paired the standard chemotherapy for pancreatic cancer, gemcitabine, with an agonist CD40 antibody.
The SHIVA trial is the first randomized trial to look at patient outcomes after treatments were chosen based on individual molecular profiles of each person's tumor.
Marked differences in the genomic terrain of the two most common types of cervical cancer suggest that patients might benefit from therapies geared to each type's molecular idiosyncrasies, according to a new study.
A specific protein has been found in nearly 100% of high-grade meningiomas, which is the most common form of brain tumor. This finding suggests a new target for therapies for a cancer that does not respond to current chemotherapy.
A newly discovered weakness in cancer cells may make them more susceptible to chemotherapy and other treatments.
In a small study, most patients given low doses of azacitidine prior to standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) remained cancer-free for up to 28 months.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|